Eugia Pharma receives USFDA Approval for Icatibant Injection
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
The product is being launched in August 2023
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
Subscribe To Our Newsletter & Stay Updated